FDA Clears Lunit's AI-Powered Digital Breast Tomosynthesis Platform
Lunit Insight DBT may facilitate improved detection and efficiency for radiologists interpreting digital breast tomosynthesis images.
The Food and Drug Administration (FDA) has granted 510(k) clearance for Lunit Insight DBT, an artificial intelligence (AI)-enabled modality that provides adjunctive assessment of digital breast tomosynthesis (DBT) images.
Using abnormality scores to quantify the malignancy likelihood of suspicious breast lesions, Lunit Insight DBT also provides information on lesion calcification and different types of soft tissue lesions, according to Lunit, the manufacturer of the modality.
In addition to enhanced visibility of highlighted lesions, Lunit emphasized that Lunit Insight DBT facilitates timely image assessment by enabling radiologists to jump to the most optimal 3D slice for viewing a suspicious lesion.
“More than 40 million mammography screenings are reported in the US annually. … Achieving FDA clearance for Lunit Insight DBT … marks a significant milestone in our mission to revolutionize breast cancer diagnosis and, ultimately, save more lives,” noted Brandon Suh, the CEO of Lunit.
GE HealthCare Launches AI Mammography Platform with Key Applications from iCAD
November 30th 2023Offering an all-in-one platform of artificial intelligence (AI) applications, MyBreastAI Suite reportedly facilitates early breast cancer detection and enhances efficiency with breast imaging workflows.
Study Shows Benefits of AI in Detecting Lung Cancer Risk in Non-Smokers
November 22nd 2023Artificial intelligence (AI) assessments of chest X-rays identified 28 percent of a 17,000 plus cohort of never-smokers as being at high-risk for lung cancer, according to research to be presented at the annual Radiological Society of North America (RSNA) conference next week.
